President Donald Trump said Sunday night that he will sign an executive order on Monday to cut the cost of prescription drugs ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

President Donald Trump said he plans to order a cut in US prescription drug costs by mandating that Americans pay no more ...

The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...

UK-based pharma major AstraZeneca and its Japanese partner Daiichi Sankyo are moving to expand the reach of their blockbuster ...

Shares of Asian pharmaceutical companies fell after US President Donald Trump said he planned to order a cut in US ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...

Daiichi Sankyo reaffirms US manufacturing expansion, including for Enhertu, will help with Trump's proposed tariffs. Ohio ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

Shares of Asia drugmakers fell on Monday after President Trump said he would sign an executive order aimed at lowering the cost of prescription drugs.